The transcription factor c-Myb can be involved in the activation of many genes with protumorigenic function; however, its role in breast cancer (BC) development is still under discussion. c-Myb is considered as a tumor-promoting factor in the early phases of BC, on the other hand, its expression in BC patients relates to a good prognosis. Previously, we have shown that c-Myb controls the capacity of BC cells to form spontaneous lung metastasis. Reduced seeding of BC cells to the lungs is linked to high expression of c-Myb and a decline in expression of a specific set of inflammatory genes. Here, we unraveled a c-Myb-IL1α-NF-κB signaling axis that takes place in tumor cells. We report that an overexpression of c-Myb interfered with the activity of NF-κB in several BC cell lines. We identified IL1α to be essential for this interference since it was abrogated in the IL1α-deficient cells. Overexpression of IL1α, as well as addition of recombinant IL1α protein, activated NF-κB signaling and restored expression of the inflammatory signature genes suppressed by c-Myb. The endogenous levels of c-Myb negatively correlated with IL1α on both transcriptional and protein levels across BC cell lines. We concluded that inhibition of IL1α expression by c-Myb reduces NF-κB activity and disconnects the inflammatory circuit, a potentially targetable mechanism to mimic the antimetastatic effect of c-Myb with therapeutic perspective.

Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic

Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic; International Clinical Research Center Center for Biological and Cellular Engineering St Anne's University Hospital Brno Czech Republic

Institute of Physiology University of Zurich and Comprehensive Cancer Center Zurich Switzerland

Zobrazit více v PubMed

Tsang JYS, Tse GM. Molecular classification of breast cancer. Adv Anat Pathol. 2020;27:27–35. doi: 10.1097/PAP.0000000000000232. PubMed DOI

Jones SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer. 2008;8:224–233. doi: 10.3816/CBC.2008.n.025. PubMed DOI

Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26:809–815. doi: 10.1158/1055-9965.EPI-16-0889. PubMed DOI PMC

Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer. 2008;8:523–534. doi: 10.1038/nrc2439. PubMed DOI

Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci U S A. 1991;88:2351–2355. doi: 10.1073/pnas.88.6.2351. PubMed DOI PMC

Waldron T, De Dominici M, Soliera AR, Audia A, Iacobucci I, Lonetti A, Martinelli G, Zhang Y, Martinez R, Hyslop T. c-Myb and its target BMI1 are required for p190BCR/ABL leukemogenesis in mouse and human cells. Leukemia. 2012;26:644–653. doi: 10.1038/leu.2011.264. PubMed DOI PMC

Tichý M, Knopfová L, Jarkovský J, Pekarčíková L, Veverková L, Vlček P, Katolická J, Čapov I, Hermanová M, Šmarda J. Overexpression of c-Myb is associated with suppression of distant metastases in colorectal carcinoma. Tumor Biol. 2016;37:10723–10729. doi: 10.1007/s13277-016-4956-7. PubMed DOI

Tichý M, Knopfová L, Jarkovský J, Vlček P, Katolická J, Čapov I, Hermanová M, Šmarda J, Beneš P. High c-Myb expression associates with good prognosis in colorectal carcinoma. J Cancer. 2019;10:1393–1397. doi: 10.7150/jca.29530. PubMed DOI PMC

Liu LYD, Chang LY, Kuo WH, Hwa HL, Chang KJ, Hsieh FJ. A supervised network analysis on gene expression profiles of breast tumors predicts a 41-gene prognostic signature of the transcription factor MYB across molecular subtypes. Comput Math Methods Med. 2014;2014 doi: 10.1155/2014/813067. PubMed DOI PMC

Miao RY, Drabsch Y, Cross RS, Cheasley D, Carpinteri S, Pereira L, Malaterre J, Gonda TJ, Anderson RL, Ramsay RG. MYB is essential for mammary tumorigenesis. Cancer Res. 2011;71:7029–7037. doi: 10.1158/0008-5472.CAN-11-1015. PubMed DOI

Nicolau M, Levine AJ, Carlsson G. Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival. Proc Natl Acad Sci U S A. 2011;108:7265–7270. doi: 10.1073/pnas.1102826108. PubMed DOI PMC

Thorner AR, Parker JS, Hoadley KA, Perou CM. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. PLoS One. 2010;5:e13073. doi: 10.1371/journal.pone.0013073. PubMed DOI PMC

Guérin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene. 1990;5:131–135. https://pubmed.ncbi.nlm.nih.gov/2181374/ PubMed

Mitra P, Pereira LA, Drabsch Y, Ramsay RG, Gonda TJ. Estrogen receptor-α recruits P-TEFb to overcome transcriptional pausing in intron 1 of the MYB gene. Nucleic Acids Res. 2012;40:5988–6000. doi: 10.1093/nar/gks286. PubMed DOI PMC

Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. SpringerPlus. 2014;3:535. doi: 10.1186/2193-1801-3-535. PubMed DOI PMC

Mitra P. Transcription regulation of MYB: a potential and novel therapeutic target in cancer. Ann Transl Med. 2018;6:443. doi: 10.21037/atm.2018.09.62. PubMed DOI PMC

Drabsch Y, Robert RG, Gonda T J. MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res. 2010;12:R55. doi: 10.1186/bcr2614. PubMed DOI PMC

Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Aldaz CM, Afshari CA, Walker CL. Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res. 2003;1:300–311. https://mcr.aacrjournals.org/content/1/4/300 PubMed

Knopfová L, Biglieri E, Volodko N, Masařík M, Hermanová M, Glaus Garzón JF, Dúcka M, Kučírková T, Souček K, Šmarda J. Transcription factor c-Myb inhibits breast cancer lung metastasis by suppression of tumor cell seeding. Oncogene. 2018;37:1020–1030. doi: 10.1038/onc.2017.392. [GSE104264] PubMed DOI PMC

Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, Johannsson O, Olsson H, Trent JM, Isola J, Borg A. MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res. 2000;60:5323–5328. https://cancerres.aacrjournals.org/content/60/19/5323 PubMed

Hugo HJ, Pereira L, Suryadinata R, Drabsch Y, Gonda TJ, Gunasinghe NPAD, Pinto C, Soo ETL, van Denderen BJW, Hill P. Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells. Breast Cancer Res. 2013;15:R113. doi: 10.1186/bcr3580. PubMed DOI PMC

Cesi V, Casciati A, Sesti F, Tanno B, Calabretta B, Raschella G. TGFβ-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER+ breast cancer cells. Cell Cycle. 2011;10(23):4149–4161. doi: 10.4161/cc.10.23.18346. PubMed DOI

Li Y, Jin K, Van Pelt GW, Van Dam H, Yu X, Mesker WE, ten Dijke P, Zhou F, Zhang L. c-Myb enhances breast cancer invasion and metastasis through the Wnt/β-catenin/Axin2 pathway. Cancer Res. 2016;76:3364–3375. doi: 10.1158/0008-5472.CAN-15-2302. PubMed DOI

Drabsch Y, Hugo H, Zhang R, Dowhan DH, Miao YR, Gewirtz AM, Barry SC, Ramsay RG, Gonda TJ. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proc Natl Acad Sci U S A. 2007;104:13762–13767. doi: 10.1073/pnas.0700104104. PubMed DOI PMC

Tanno B, Sesti F, Cesi V, Bossi G, Ferrari-Amorotti G, Bussolari R, Tirindelli D, Calabretta B, Raschellà G. Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin. J Biol Chem. 2010;285:29434–29445. doi: 10.1074/jbc.M109.089045. PubMed DOI PMC

Kim D, You E, Jeong J, Ko P, Kim J-W, Rhee S. DDR2 controls the epithelial-mesenchymal-transition-related gene expression via c-Myb acetylation upon matrix stiffening. Sci Rep. 2017;7:6847. doi: 10.1038/s41598-017-07126-7. PubMed DOI PMC

Staudt LM. Oncogenic activation of NF-κB. Cold Spring Harb Perspect Biol. 2010;2 https://dx.doi.org/10.1101%2Fcshperspect.a000109. PubMed PMC

Bennett L, Quinn J, McCall P, Mallon EA, Horgan PG, McMillan DC, Paul A, Edwards J. High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer. Int J Cancer. 2017;140:1633–1644. doi: 10.1002/ijc.30578. PubMed DOI

Sirinian C, Papanastasiou AD, Schizas M, Spella M, Stathopoulos GT, Repanti M, Zarkadis IK, King TA, Kalofonos HP. RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling. Oncogene. 2018;37:5101–5114. doi: 10.1038/s41388-018-0324-y. PubMed DOI

Espinoza-Sánchez NA, Győrffy B, Fuentes-Pananá EM, Götte M. Differential impact of classical and non-canonical NF-κB pathway-related gene expression on the survival of breast cancer patients. J Cancer. 2019;10:5191–5211. doi: 10.7150/jca.34302. PubMed DOI PMC

Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–310. doi: 10.1038/nrc780. PubMed DOI

Malik A, Kanneganti T-D. Function and regulation of IL-1α in inflammatory diseases and cancer. Immunol Rev. 2018;281:124–137. doi: 10.1111/imr.12615. PubMed DOI PMC

Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010;3 doi: 10.1126/scisignal.3105cm1. cm1. PubMed DOI

Liu S, Lee JS, Jie C, Park MH, Iwakura Y, Patel Y, Soni M, Reisman D, Chen H. HER2 overexpression triggers an IL1α proinflammatory circuit to drive tumorigenesis and promote chemotherapy resistance. Cancer Res. 2018;78:2040–2051. doi: 10.1158/0008-5472.CAN-17-2761. PubMed DOI PMC

Kumar S, Kishimoto H, Chua HL, Badve S, Miller KD, Bigsby RM, Nakshatri H. Interleukin-1α promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am J Pathol. 2003;163:2531–2541. doi: 10.1016/S0002-9440(10)63608-5. PubMed DOI PMC

Kuan EL, Ziegler SF. A tumor–myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer. Nat Immunol. 2018;19:366–374. doi: 10.1038/s41590-018-0066-6. PubMed DOI PMC

Roberti MP, Arriaga JM, Bianchini M, Quintá HR, Bravo AI, Levy EM, Mordoh J, Barrio MM. Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther. 2012;13:1123–1140. doi: 10.4161/cbt.21187. PubMed DOI PMC

Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE, Ottewell P. IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget. 2016;7:75571–75584. doi: 10.18632/oncotarget.12289. PubMed DOI PMC

Johnstone CN, Smith YE, Cao Y, Burrows AD, Cross RSN, Ling X, Redvers RP, Doherty JP, Eckhardt BL, Natoli AL. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Model Mech. 2015;8:237–251. doi: 10.1242/dmm.017830. PubMed DOI PMC

Smarda J, Sugarman J, Glass C, Lipsick J. Retinoic acid receptor α suppresses transformation by v-myb. Mol Cell Biol. 1995;15:2474–2481. doi: 10.1128/mcb.15.5.2474. PubMed DOI PMC

Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Stürzl M. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell. 2012;22:91–105. doi: 10.1016/j.ccr.2012.05.023. PubMed DOI

Volodko N, Gutor T, Petronchak O, Huley R, Dúcka M, Šmarda J, Borsig L, Beneš P, Knopfová L. Low infiltration of tumor-associated macrophages in high c-Myb-expressing breast tumors. Sci Rep. 2019;9:11634. doi: 10.1038/s41598-019-48051-1. PubMed DOI PMC

Williams MR, Sakurai Y, Zughaier SM, Eskin SG, McIntire L V. Transmigration across activated endothelium induces transcriptional changes, inhibits apoptosis, and decreases antimicrobial protein expression in human monocytes. J Leukoc Biol. 2009;86:1331–1343. doi: 10.1189/jlb.0209062. GSE14027] PubMed DOI PMC

Drake JM, Strohbehn G, Bair TB, Moreland JG, Henry MD. ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell. 2009;20:2207–2217. GSE14405] https://dx.doi.org/10.1091%2Fmbc.E08-10-1076. PubMed PMC

Jiang G, Zhang S, Yazdanparast A, Li M, Pawar AV, Liu Y, Inavolu SM, Cheng L. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics. 2016;17:525. doi: 10.1186/s12864-016-2911-z. PubMed DOI PMC

Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017;8:3131–3141. doi: 10.7150/jca.18457. PubMed DOI PMC

Yamaguchi N, Ito T, Azuma S, Ito E, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Watanabe S. Constitutive activation of nuclear factor-κB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci. 2009;100:1668–1674. doi: 10.1111/j.1349-7006.2009.01228.x. PubMed DOI PMC

Zhao L, Glazov EA, Pattabiraman DR, Al-Owaidi F, Zhang P, Brown MA, Leo PJ, Gonda TJ. Integrated genome-wide chromatin occupancy and expression analyses identify key myeloid pro-differentiation transcription factors repressed by Myb. Nucleic Acids Res. 2011;39:4664–4679. doi: 10.1093/nar/gkr024. PubMed DOI PMC

Sandberg ML, Sutton SE, Pletcher MT, Wiltshire T, Tarantino LM, Hogenesch JB, Cooke MP. c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell. 2005;8:153–166. doi: 10.1016/j.devcel.2004.12.015. PubMed DOI

Pereira LA, Hugo HJ, Malaterre J, Huiling X, Sonza S, Cures A, Purcell DFJ, Ramsland PA, Gerondakis S, Gonda TJ. MYB elongation is regulated by the nucleic acid binding of NFkB p50 to the intronic stem-loop region. PLoS One. 2015;10 doi: 10.1371/journal.pone.0122919. PubMed DOI PMC

Shin HM, Kim MH, Kim BH, Jung SH, Kim YS, Park HJ, Hong JT, Min KR, Kim Y. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-κB without affecting IκB degradation. FEBS Lett. 2004;571:50–54. doi: 10.1016/j.febslet.2004.06.056. PubMed DOI

Niu J, Li Z, Peng B, Chiao PJ. Identification of an autoregulatory feedback pathway involving interleukin-1α in induction of constitutive NF-κB activation in pancreatic cancer cells. J Biol Chem. 2004;279:16452–16462. doi: 10.1074/jbc.M309789200. PubMed DOI

Bauer D, Redmon N, Mazzio E, Soliman KF. Apigenin inhibits TNFα/IL-1α-induced CCL2 release through IKBK-epsilon signaling in MDA-MB-231 human breast cancer cells. PLoS One. 2017;12 doi: 10.1371/journal.pone.0175558. PubMed DOI PMC

Mathes E, O'Dea EL, Hoffmann A, Ghosh G. NF-κB dictates the degradation pathway of IκBα. EMBO J. 2008;27:1357–1367. doi: 10.1038/emboj.2008.73. PubMed DOI PMC

Annunziato S, de Ruiter JR, Henneman L, Brambillasca CS, Lutz C, Vaillant F, Ferrante F, Drenth AP, van der Burg E, Siteur B. Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. Nat Commun. 2019;10:397. doi: 10.1038/s41467-019-08301-2. PubMed DOI PMC

Wellenstein MD, Coffelt SB, Duits DEM, van Miltenburg MH, Slagter M, de Rink I, Henneman L, Kas SM, Prekovic S, Hau CS. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature. 2019;572:538–542. doi: 10.1038/s41586-019-1450-6. [GSE112665] PubMed DOI PMC

Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, Dirix LY, Van Laere SJ. The interaction between ER and NFкB in resistance to endocrine therapy. Breast Cancer Res. 2012;14:212. doi: 10.1186/bcr3196. PubMed DOI PMC

Dai P, Akimaru H, Tanaka Y, Hou D-X, Yasukawa T, Kanei-Ishii C, Takahashi T, Ishii S. CBP as a transcriptional coactivator of c-Myb. Genes Dev. 1996;10:528–540. doi: 10.1101/gad.10.5.528. PubMed DOI

Kasper L H, Fukuyama T, Lerach S, Chang Y, Xu W, Wu S, Boyd K L, Brindle P K. Genetic interaction between mutations in c-Myb and the KIX domains of CBP and p300 affects multiple blood cell lineages and influences both gene activation and repression. PLoS One. 2013;8:e82684. doi: 10.1371/journal.pone.0082684. PubMed DOI PMC

Tafessu A, Banaszynski L A. Establishment and function of chromatin modification at enhancers: chromatin landscape at enhancers. Open Biol. 2020;10 doi: 10.1098/rsob.200255. PubMed DOI PMC

Timblin GA, Xie L, Tjian R, Schlissel MS. Dual mechanism of Rag Gene repression by c-Myb during pre-B cell proliferation. Mol Cell Biol. 2017;37:e00437. doi: 10.1128/MCB.00437-16. 16. PubMed DOI PMC

Ledsaak M, Bengtsen M, Molværsmyr AK, Fuglerud BM, Matre V, Eskeland R, Gabrielsen OS. PIAS1 binds p300 and behaves as a coactivator or corepressor of the transcription factor c-Myb dependent on SUMO-status. Biochim Biophys Acta - Gene Regul Mech. 2016;1859:705–718. doi: 10.1016/j.bbagrm.2016.03.011. PubMed DOI

Kasper LH, Qu C, Obenauer JC, McGoldrick DJ, Brindle PK. Genome-wide and single-cell analyses reveal a context dependent relationship between CBP recruitment and gene expression. Nucleic Acids Res. 2014;42:11363–11382. doi: 10.1093/nar/gku827. PubMed DOI PMC

Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12:115–130. doi: 10.1016/j.ccr.2007.07.004. PubMed DOI PMC

Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG, Ethier SP. Activation of a nuclear factor κB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells. Mol Cancer Res. 2007;5:847–861. doi: 10.1158/1541-7786.MCR-06-0427. PubMed DOI

Tjomsland V, Spångeus A, Välilä J, Sandström P, Borch K, Druid H, Falkmer S, Falkmer U, Messmer D, Larsson M. Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia. 2011;13:664–675. doi: 10.1593/neo.11332. PubMed DOI PMC

Bhat-Nakshatri P, Newton TR, Goulet RJ, Nakshatri H. NF-κB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1α. Proc Natl Acad Sci USA. 1998;95:6971–6976. doi: 10.1073/pnas.95.12.6971. PubMed DOI PMC

Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, Barrows G, Kreutzer DL. The interleukin-1 family of cytokines and receptors in human breast cancer : Implications for tumor progression. Int J Oncol. 2003;23:269–284. doi: 10.3892/ijo.23.2.269. PubMed DOI

Morishita M, Miyagi M, Iwamoto Y. Effects of sex hormones on production of interleukin-1 by human peripheral monocytes. J Periodontol. 1999;70:757–760. doi: 10.1902/jop.1999.70.7.757. PubMed DOI

Pfeilschifter J, Köditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002;23:90–119. doi: 10.1210/edrv.23.1.0456. PubMed DOI

The FANTOM Consortium and the Riken Omics Science Center The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet. 2009;41:553–562. doi: 10.1038/ng.375. PubMed DOI PMC

Quintana AM, Liu F, O'Rourke JP, Ness SA. Identification and regulation of c-Myb target genes in MCF-7 cells. BMC Cancer. 2011;11:30. doi: 10.1186/1471-2407-11-30. PubMed DOI PMC

Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15:416–428. doi: 10.1016/j.ccr.2009.03.016. PubMed DOI PMC

Luo M, Hou L, Li J, Shao S, Huang S, Meng D, Liu L, Feng L, Xia P, Qin T, Zhao X. VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin. Cancer lett. 2016;373:1–11. doi: 10.1016/j.canlet.2016.01.010. PubMed DOI

Häuselmann I, Roblek M, Protsyuk D, Huck V, Knopfova L, Grässle S, Bauer AT, Schneider SW, Borsig L. Monocyte induction of E-selectin-mediated endothelial activation releases VE-cadherin junctions to promote tumor cell extravasation in the metastasis cascade. Cancer Res. 2016;76:5302–5312. doi: 10.1158/0008-5472.CAN-16-0784. PubMed DOI PMC

Roblek M, Protsyuk D, Becker PF, Stefanescu C, Gorzelanny C, Glaus Garzon JF, Knopfova L, Heikenwalder M, Luckow B, Schneider SW. CCL2 is a vascular permeability factor inducing CCR2-dependent endothelial retraction during lung metastasis. Mol Cancer Res. 2019;17:783–793. doi: 10.1158/1541-7786.MCR-18-0530. PubMed DOI PMC

Dagenais M, Dupaul-Chicoine J, Douglas T, Champagne C, Morizot A, Saleh M. The interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis. Oncoimmunology. 2017;6 doi: 10.1080/2162402X.2017.1287247. PubMed DOI PMC

Wellenstein MD, de Visser KE. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity. 2018;48:399–416. doi: 10.1016/j.immuni.2018.03.004. PubMed DOI

Transcription factor c-Myb: novel prognostic factor in osteosarcoma